Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
01
10
2019
accepted:
02
12
2019
revised:
22
11
2019
pubmed:
18
12
2019
medline:
22
6
2021
entrez:
18
12
2019
Statut:
ppublish
Résumé
In the absence of an HLA-matched donor, the best treatment for acquired aplastic anemia patients refractory to immunosuppression is unclear. We collected and analyzed data from all acquired aplastic anemia patients who underwent a haploidentical transplantation with posttransplant cyclophosphamide in Europe from 2011 to 2017 (n = 33). The cumulative incidence of neutrophil engraftment was 67% (CI
Identifiants
pubmed: 31844137
doi: 10.1038/s41409-019-0773-0
pii: 10.1038/s41409-019-0773-0
doi:
Substances chimiques
Cyclophosphamide
8N3DW7272P
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1050-1058Références
Young NS. Aplastic anemia. N. Engl J Med. 2018;379:1643–56.
doi: 10.1056/NEJMra1413485
Bacigalupo A. How I treat acquired aplastic anemia. Blood. 2017;129:1428–36.
doi: 10.1182/blood-2016-08-693481
Peffault de Latour R. Transplantation for bone marrow failure: current issues. Hematology. 2016;90–8.
Scheinberg P, Cooper JN, Sloand EM, Wu CO, Calado RT, Young NS. Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia. JAMA. 2010;304:1358–64.
doi: 10.1001/jama.2010.1376
Olnes MJ, Scheinberg P, Calvo KR, Desmond R, Tang Y, Dumitriu B, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N. Engl J Med. 2012;367:11–9.
doi: 10.1056/NEJMoa1200931
Townsley DM, Olnes MJ, Broder K, Scheinberg P, Desmond R, Bevans M, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2013;123:1818–25.
pubmed: 24345753
Lengline E, Drenou B, Peterlin P, Tournilhac O, Abraham J, Berceanu A, et al. Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the french reference center for aplastic anemia. Haematologica. 2018;103:212–20.
doi: 10.3324/haematol.2017.176339
Cle DV, Atta EH, Dias DSP, Lima CBL, Bonduel M, Sciuccati G, et al. Repeat course of rabbit antithymocyte globulin as salvage following initial therapy with rabbit antithymocyte globulin in acquired aplastic anemia. Haematologica. 2015;100:e345–7.
doi: 10.3324/haematol.2015.123760
Trcuelu A, Passweg J, Nissen C, Bargetzi M, Hoffmann T, Signer E, et al. Repeated treatment with horse antilymphocyte globulin for severe aplastic anaemia. Br J Haematol. 1998;100:393–400.
doi: 10.1046/j.1365-2141.1998.00578.x
Yoshizato T, Dumitriu B, Hosokawa K, Makishima H, Yoshida K, Townsley D, et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. N. Engl J Med. 2015;373:35–47.
doi: 10.1056/NEJMoa1414799
Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood. 2014;120:1185–96.
doi: 10.1182/blood-2011-12-274019
Bacigalupo A. Alternative donor transplants for severe aplastic anemia. Hematology. 2018;467–73.
Luznik L, Donnell PVO, Symons HJ, Chen AR, Susan M, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transpl. 2008;14:641–50.
doi: 10.1016/j.bbmt.2008.03.005
European Society for Blood and Marrow Transplantation. MED-AB forms manual a guide to the completion of the EBMT HSCT Med-AB forms [Internet]. 2018. p. 1–152. https://www.ebmt.org/sites/default/files/2018-03/MED-AB Forms Manual.pdf .
Battipaglia G, Ruggeri A, Labopin M, Volin L, Blaise D, Socie G, et al. Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemia. Bone Marrow Transpl. 2018;53:1295–303.
doi: 10.1038/s41409-018-0169-6
Iacobelli S. Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation. Bone Marrow Transpl. 2013;48:S1–37.
doi: 10.1038/bmt.2012.282
Valdez JM, Scheinberg P, Nunez O, Wu CO, Young NS, Walsh TJ. Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades. Clin Infect Dis. 2011;52:726–35.
doi: 10.1093/cid/ciq245
Devillier R, Dalle J-HH, Kulasekararaj A, D’aveni M, Clément L, Chybicka A, et al. Unrelated alternative donor transplantation for severe acquired aplastic anemia: a study from the french society of bone marrow transplantation and cell therapies and the EBMT severe aplastic anemia working party. Haematologica. 2016;101:884–90.
doi: 10.3324/haematol.2015.138727
Maury S, Chir Z, Boiron J, Galambrun C, Yakouben K, Bordigoni P, et al. Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient. Haematologica. 2007;92:589–96.
doi: 10.3324/haematol.10899
Socie G, Henry-Amar M, Bacigalupo A, Hows J, Tichelli A, Ljungman P, et al. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. N. Engl J Med. 1993;329:1152–7.
doi: 10.1056/NEJM199310143291603
Peffault de Latour R, Purtill D, Ruggeri A, Sanz G, Michel G, Gandemer V, et al. Influence of nucleated cell dose on overall survival of unrelated cord blood transplantation for patients with severe acquired aplastic anemia: a study by eurocord and the aplastic anemia working party of the european group for blood and marrow transplant. Biol Blood Marrow Transpl. 2011;17:78–85.
doi: 10.1016/j.bbmt.2010.06.011
Peffault de Latour R, Chevret S, Jubert C, Sirvent A, Galambrun C, Ruggeri A, et al. Unrelated cord blood transplantation in patients with idiopathic refractory severe aplastic anemia: a nationwide phase 2 study. Blood. 2018;132:750–4.
doi: 10.1182/blood-2018-01-829630
Horan J, Wang T, Haagenson M, Ayas M, Baxter-Lowe LA, Bielorai B, et al. Evaluation of HLA matching requirements in unrelated hematopoietic stem cell transplantation for nonmalignant disorders. Blood. 2012;120:2918–24.
doi: 10.1182/blood-2012-03-417758
Yagasaki H, Kojima S, Yabe H, Kato K, Kigasawa H, Sakamaki H, et al. Acceptable HLA-mismatching in unrelated donor bone marrow transplantation for patients with acquired severe aplastic anemia. Blood. 2011;118:3186–90.
doi: 10.1182/blood-2011-04-349316
Passweg JR, Përez WS, Eapen M, Camitta BM, Gluckman E, Hinterberger W, et al. Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia. Bone Marrow Transpl. 2006;37:641–9.
doi: 10.1038/sj.bmt.1705299
Kim H, Im HJ, Koh K-N, Kang SH, Yoo JW, Choi ES, et al. Comparable outcome with a faster engraftment of optimized haploidentical hematopoietic stem cell transplantation compared with transplantations from other donor types in pediatric acquired aplastic anemia. Biol Blood Marrow Transpl. 2019;25:965–74.
doi: 10.1016/j.bbmt.2019.01.010
Im HJ, Koh KN, Seo JJ, Choi ES, Jang S, Kwon SW, et al. Excellent outcome of haploidentical hematopoietic stem cell transplantation in children and adolescents with acquired severe aplastic anemia. Biol Blood Marrow Transpl. 2013;19:754–9.
doi: 10.1016/j.bbmt.2013.01.023
Gao L, Li Y, Zhang Y, Chen X, Gao L, Zhang C, et al. Long-term outcome of HLA-haploidentical hematopoietic SCT without in vitro T-cell depletion for adult severe aplastic anemia after modified conditioning and supportive therapy. Bone Marrow Transpl. 2014;49:519–24.
doi: 10.1038/bmt.2013.224
Li XH, Gao CJ, Da WM, Bin CaoY, Wang ZH, Xu LX, et al. Reduced intensity conditioning, combined transplantation of haploidentical hematopoietic stem cells and mesenchymal stem cells in patients with severe aplastic anemia. PLoS ONE. 2014;9:1–7.
Yamei W, Rongmu L, Yongbin C, Yingjian S, Xiaohong L. Improved outcome of haploidentical transplantation in severe aplastic anemia using reduced-intensity fludarabine-based conditioning. Oncotarget. 2017;8:83817–30.
doi: 10.18632/oncotarget.19745
Xu ZL, Zhou M, Jia JS, Mo WJ, Zhang XH, Zhang YP, et al. Immunosuppressive therapy versus haploidentical transplantation in adults with acquired severe aplastic anemia. Bone Marrow Transpl. 2019;54:1319–26.
doi: 10.1038/s41409-018-0410-3
Zhu H, Luo RM, Luan Z, Lee V, Zhu YP, Luo CJ, et al. Unmanipulated haploidentical haematopoietic stem cell transplantation for children with severe aplastic anaemia. Br J Haematol. 2016;174:799–805.
doi: 10.1111/bjh.14110
Yang S, Yuan X, Ma R, Jiang L, Guo J, Zang Y, et al. Comparison of outcomes of frontline immunosuppressive therapy and frontline haploidentical hematopoietic stem cell transplantation for children with severe aplastic anemia who lack an HLA-matched sibling donor. Biol Blood Marrow Transpl. 2019;25:975–80.
doi: 10.1016/j.bbmt.2019.01.017
Xu LP, Jin S, Wang SQ, Xia LH, Bai H, Gao SJ, et al. Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant. J Hematol Oncol. 2017;10:1–10.
doi: 10.1186/s13045-016-0379-6
Xu L-PP, Wang S-QQ, Wu D-PP, Wang J-MM, Gao S-JJ, Jiang M, et al. Haplo-identical transplantation for acquired severe aplastic anaemia in a multicentre prospective study. Br J Haematol. 2016;175:265–74.
doi: 10.1111/bjh.14225
Esteves I, Bonfim C, Pasquini R, Funke V, NF P, Rocha V, et al. Haploidentical BMT and post-transplant Cy for severe aplastic anemia: a multicenter retrospective study. Bone Marrow Transpl. 2015;50:685–9.
doi: 10.1038/bmt.2015.20
Clay J, Kulasekararaj AG, Potter V, Grimaldi F, McLornan D, Raj K, et al. Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia. Biol Blood Marrow Transpl. 2014;20:1711–6.
doi: 10.1016/j.bbmt.2014.06.028
DeZern AE, Zahurak M, Symons H, Cooke K, Jones RJ, Brodsky RA. Alternative donor transplantation with high-dose post-transplantation cyclophosphamide for refractory severe aplastic anemia. Biol Blood Marrow Transpl. 2017;23:498–504.
doi: 10.1016/j.bbmt.2016.12.628
Anderlini P, Wu J, Gersten I, Ewell M, Tolar J, Antin JH, et al. Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1–2 dose de-escalation study. Lancet Haematol. 2015;2:e367–75.
doi: 10.1016/S2352-3026(15)00147-7
Deeg HJ, Amylon ID, Harris RE, Collins R, Beatty PG, Feig S, et al. Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol Blood Marrow Transpl. 2001;7:208–15.
doi: 10.1053/bbmt.2001.v7.pm11349807
Bacigalupo A, Socie G, Hamladji RM, Aljurf M, Maschan A, Kyrcz-Krzemien S, et al. Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: An EBMT analysis. Haematologica. 2015;100:696–702.
doi: 10.3324/haematol.2014.115345
Giammarco S, Peffault de Latour R, Sica S, Dufour C, Socie G, Passweg J, et al. Transplant outcome for patients with acquired aplastic anemia over the age of 40: has the outcome improved? Blood. 2018;131:blood-2018-01-826495.
Bacigalupo A, Socié G, Schrezenmeier H, Tichelli A, Locasciulli A, Fuehrer M, et al. Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: Survival advantage for bone marrow in all age groups. Haematologica. 2012;97:1142–8.
doi: 10.3324/haematol.2011.054841
Schrezenmeier H, Passweg JR, Marsh JCW, Bacigalupo A, Bredeson CN, Bullorsky E, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood. 2007;110:1397–400.
doi: 10.1182/blood-2007-03-081596
Gorin C. Bone marrow harvesting for HSCT. In: Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT handbook. Cham, Switzerland: Springer Open; 2019. p. 109–16.
Hübel K. Mobilization and collection of HSC. In: Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT handbook. Cham, Switzerland: Springer Open; 2019. p. 117–24.